Michael Chi Sells 17,102 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Michael Chi sold 17,102 shares of the stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $59.75, for a total value of $1,021,844.50. Following the completion of the sale, the insider now owns 278,654 shares of the company’s stock, valued at $16,649,576.50. The trade was a 5.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Michael Chi also recently made the following trade(s):

• On Tuesday, June 10th, Michael Chi sold 5,600 shares of Hims & Hers Health stock. The shares were sold at an average price of $57.00, for a total value of $319,200.00.
• On Friday, June 6th, Michael Chi sold 5,100 shares of Hims & Hers Health stock. The shares were sold at an average price of $56.00, for a total value of $285,600.00.

Hims & Hers Health Trading Up 3.1%

Shares of Hims & Hers Health stock opened at $61.09 on Thursday. The business has a 50-day moving average price of $47.00 and a two-hundred day moving average price of $38.75. Hims & Hers Health, Inc. has a 1-year low of $13.47 and a 1-year high of $72.98. The company has a market cap of $13.67 billion, a P/E ratio of 88.54, a PEG ratio of 2.23 and a beta of 2.09.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.12 by $0.08. The company had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. The firm’s revenue for the quarter was up 110.7% compared to the same quarter last year. During the same period last year, the business posted $0.05 EPS. Equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Institutional Trading of Hims & Hers Health

Several large investors have recently made changes to their positions in the company. Smartleaf Asset Management LLC grew its stake in shares of Hims & Hers Health by 15.7% in the 1st quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company’s stock valued at $49,000 after buying an additional 227 shares during the period. Allworth Financial LP grew its stake in shares of Hims & Hers Health by 20.0% in the 1st quarter. Allworth Financial LP now owns 2,006 shares of the company’s stock valued at $56,000 after buying an additional 334 shares during the period. Signaturefd LLC grew its stake in shares of Hims & Hers Health by 17.7% in the 1st quarter. Signaturefd LLC now owns 2,586 shares of the company’s stock valued at $76,000 after buying an additional 388 shares during the period. SlateStone Wealth LLC lifted its position in Hims & Hers Health by 4.0% in the 4th quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock valued at $257,000 after acquiring an additional 413 shares in the last quarter. Finally, Kilter Group LLC lifted its position in Hims & Hers Health by 1.0% in the 1st quarter. Kilter Group LLC now owns 43,989 shares of the company’s stock valued at $1,300,000 after acquiring an additional 450 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

HIMS has been the subject of a number of recent research reports. Truist Financial decreased their price objective on Hims & Hers Health from $39.00 to $33.00 and set a “hold” rating for the company in a report on Thursday, April 10th. Canaccord Genuity Group increased their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Needham & Company LLC increased their price objective on Hims & Hers Health from $61.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, June 4th. Morgan Stanley restated an “equal weight” rating and issued a $40.00 price objective on shares of Hims & Hers Health in a report on Wednesday, June 11th. Finally, UBS Group reiterated a “mixed” rating on shares of Hims & Hers Health in a report on Tuesday, May 6th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Hims & Hers Health has an average rating of “Hold” and a consensus target price of $38.00.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.